Maria J. Matos
“Nothing in life is to be feared; it is only to be understood.” Marie Curie
Publications
Author of 139 peer-reviewed papers: 79 as corresponding author and 54 as first author. The citation count from Google Scholar is a total of 6283 (August 2024), resulting in an h-index of 44. Author of 50 refereed conference publications (proceedings), 176 conference abstracts (118 poster and 58 oral communications), 5 book chapters and 2 patents. Corresponding author is marked with *.
2024
139. A New Class of Benzo[b]thiophene-chalcones as Cholinesterase Inhibitors: Synthesis, Biological Evaluation, Molecular Docking and ADME Studies (Delogu GL, Begala M, Matos MJ*, Crucitti D, Sogos V, Era B, Fais A) Molecules 2024, 29(16), 3748. DOI: 10.3390/molecules29163748.
138. Seaweeds as Source of Bioactive Pigments with Neuroprotective and/or Anti-Neurodegenerative Activities: Astaxanthin and Fucoxanthin (Guardado Yordi E, Pérez Martínez A, Radice M, Scalvenzi L, Abreu-Naranjo R, Uriarte E, Santana L, Matos MJ*) Mar Drugs 2024, 22, 327. DOI: https://doi.org/10.3390/md22070327.
137. Empowering Voices: Inspiring Women in Medicinal Chemistry (Blanco MJ, Bronson JJ, DiMauro EF, Dzierba C, Eggen M, Garner AL, Georg G, Giarolla J, Goodwin NC, Grenier-Davies MC, Haskell-Luevano C, Holzgrabe U, Huang R, Lagiakos HR, Leftheris K, Martin Y, Matos MJ, May-Dracka TL, Müller CE, Newman AH, Parmee E, Petter JC, Tamayo NA, Wexler RR, Bolognesi ML, Ripka A, Young W) J Med Chem 2024 DOI: 10.1021/acs.jmedchem.4c00493.
136. Empowering Voices: Inspiring Women in Medicinal Chemistry (Blanco MJ, Bronson JJ, DiMauro EF, Dzierba C, Eggen M, Garner AL, Georg G, Giarolla J, Goodwin NC, Grenier-Davies MC, Haskell-Luevano C, Holzgrabe U, Huang R, Lagiakos HR, Leftheris K, Martin Y, Matos MJ, May-Dracka TL, Müller CE, Newman AH, Parmee E, Petter JC, Tamayo NA, Wexler RR, Bolognesi ML, Ripka A, Young W) ACS Med Chem Lett 2024 DOI: 10.1021/acsmedchemlett.4c00097.
135. N-(coumarin-3-yl)cinnamamide promotes immunomodulatory, neuroprotective, and lung function-preserving effects during severe malaria (Gaio P, Cramer A, de Melo Oliveira NF, Porto S, Kramer L, Nonato Rabelo RA, Pereira RD, de Oliveira Santos LL, Nascimento Barbosa CL, Silva Oliveira FM, Martins Teixeira M, Castro Russo R, Matos MJ*, Simão Machado F) Pharmaceuticals 2024, 17(1), 46. DOI: https://doi.org/10.3390/ph17010046
134. Study of the DNA damage and cell death in human peripheral blood mononuclear and HepG2/C3A cells exposed to the synthetic 3-(3-hydroxyphenyl)-7-hydroxycoumarin (Pereira AR, Silva Campos A, Matos MJ, Maistro EL) Journal of Toxicology and Environmental Health, Part A 2024, 87(1), 33–46. DOI: 10.1080/15287394.2023.2274331.
2023
133. Design of 3-phenylcoumarins and 3-thienylcoumarins as potent xanthine oxidase inhibitors: synthesis, biological evaluation and docking studies (Fais A, Pintus F, Era B, Floris S, Kumar A, Sarmadhikari D, Sogos V, Uriarte E, Asthana S, Matos MJ*) ChemMedChem 2023, 18, e202300. DOI: 10.1002/cmdc.202300400.
132. Evaluation of in vitro Cytotoxic and Genotoxic Effects of the 3-(3,4-Dihydroxyphenyl)-8-hydroxycoumarin (dos Santos Silva E, Matos MJ, Maistro EL) J Appl Toxicol 2023, 43, 1488–1498. DOI: 10.1002/jat.4479.
131. Oxidation-labile linkers for controlled drug delivery (Carneiro A, Santana L, Matos MJ*) Bioorg Med Chem Lett 2023, 87, 129264. DOI: 10.1016/j.bmcl.2023.129264.
130. In-silico approaches to develop new phenyl-pyrimidines as glycogen synthase kinase 3 (GSK-3) inhibitors with halogen-bonding capabilities: 3D-QSAR CoMFA/CoMSIA, molecular docking and molecular dynamics (Cabezas D, Mellado G, Espinoza N, Gárate JA, Morales C, Castro-Alvarez A, Matos MJ, Mellado M, Mella J) J Biomol Struct Dyn 2023, 41(22), 13250-13259. DOI: 10.1080/07391102.2023.2172457.
129. Propargylamine: an important moiety in drug discovery (Carneiro A, Uriarte E, Borges F, Matos MJ*) Fut Med Chem 2023, 15(2), 211−224. DOI: 10.4155/fmc-2022-0243.
128. 8-Amide and 8-carbamate substitution patterns as modulators of 7-hydroxy-4-methylcoumarin's antidepressant profile: Synthesis, biological evaluation and docking studies (Matos MJ*, Novo P, Mayán L, Torres I, Uriarte E, Yáñez M, Fontenla JA, Ortuso F, Alcaro S, Procopio F, Rodríguez-Franco MI, Val C, Loza MI, Brea J, Borges F, Viña D) Eur J Med Chem 2023, 115091. DOI: 10.1016/j.ejmech.2023.115091.
127. Recent advances in biologically active coumarins from marine sources: synthesis and evaluation
(Fernández-Peña L, Matos MJ, López E) Marine Drugs 2023, 21, 37. DOI: 10.3390/md21010037.
126. Cytogenotoxicity assessment of 3-(3,4-dihydroxyphenyl)-7,8-dihydroxycoumarin on HepG2/C3A cells and leukocytes (Martins Castanha AP, Moura Almeida-Terassi L, Guardado-Yordi E, Matos MJ, Maistro EL) J Appl Toxicol. 2023, 43, 323–334. DOI: 10.1002/jat.4384.
2022
125. Hydroxy-3-Phenylcoumarins as Multitarget Compounds for Skin Aging Diseases: Synthesis, Molecular Docking and Tyrosinase, Elastase, Collagenase and Hyaluronidase Inhibition, and Sun Protection Factor (Pintus F, Floris S, Fais A, Era B, Kumar A, Gatto G, Uriarte E, Matos MJ*) Molecules 2022, 27, 6914. DOI: 10.3390/molecules27206914.
124. Synthesis and vasorelaxant activity of nitrate-coumarin derivatives (Matos MJ*, Uriarte E, Seoane N, Picos A, Gil-Longo J, Campos-Toimil M) ChemMedChem 2022, e202200476. DOI: 10.1002/cmdc.202200476
123. Thiocoumarins: From the Synthesis to the Biological Applications (Matos MJ*, Santana L, Uriarte E, Borges F) Molecules 2022, 27, 4901. DOI: 10.3390/molecules27154901.
122. Medicinal Chemistry in Portugal and Spain: A Strong Iberian Alliance (Matos MJ*, Blanco M-J) ACS Med Chem Lett 2022, 13, 871−872. DOI: 10.1021/acsmedchemlett.2c00194.
121. Treating neurodegenerative diseases with multitarget drugs: an interview with Maria João Matos (Matos MJ*) Fut Med Chem 2022, 14(12), 847-850. DOI: 10.4155/fmc-2022-0077.
120. A Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates built using Acetal-based Linkers and Thiol-maleimide Chemistry (Ferhati X, Jiménez-Moreno E, Hoyt E, Salluce G, Cabeza-Cabrerizo M, Navo C, Compañon I, Akkapeddi P, Matos MJ, Salaverri N, Garrido P, Martinez A, Laserna V, Murray T, Jiménez-Osés G, Ravn P, Bernardes GJL, Corzana F) JACS 2022, 12, 5284-5294. DOI: 10.1021/jacs.1c07675.
119. A comprehensive ethnobotanical profile of Ocimum campechianum (Lamiaceae): from traditional medicine to phytochemical and pharmacological evidences (Guardado Yordi E, Matos MJ, Buso P, Pérez Martínez A, Asanza M, Scalvenzi L, Manfredini S, Tacchini M, Radice M, Sacchetti G) Plant Biosystems 2022. DOI: 10.1080/11263504.2022.2056647.
118. Structural insight of new butyrylcholinesterase inhibitors based on benzylbenzofuran scaffold (Delogu GL, Fais A, Pintus F, Goyal C, Matos MJ, Era B, Kumar A) Pharmaceuticals 2022, 15, 304. DOI: 10.3390/ph15030304.
117. Synthesis and study of the trypanocidal activity of catechol-containing 3-arylcoumarins, inclusion in β-cyclodextrin complexes and combination with benznidazole (Pozo-Martínez J, Salgado F, Liempi A, Kemmerling U, Mera-Adasme R, Olea-Azar C, Moncada-Basualto M, Borges F, Uriarte E, Matos MJ*) Arab J Chem 2022, 15, 103641. DOI: 10.1016/j.arabjc.2021.103641.
116. Coumarin-Resveratrol-Inspired Hybrids as Monoamine Oxidase B Inhibitors: 3-Phenylcoumarin versus trans-6-Styrylcoumarin (Mellado M, González C, Mella J, Aguilar LF, Celik I, Borges F, Uriarte E, Delogu G, Viña D, Matos MJ*) Molecules 2022, 27, 928. DOI: 10.3390/molecules27030928.
2021
115. 3-Phenylcoumarins as a privileged scaffold in Medicinal Chemistry: The landmarks of the past decade (Matos MJ*, Uriarte E, Santana L) Molecules 2021, 26, 6755. DOI: 10.3390/molecules26216755.
114. Computer-aided design of coumarins for neurodegenerative diseases: Trends of the last decade (Guardado Yordi E, Santana L, Uriarte E, Borges F, Matos MJ*) Curr Top Med Chem 2021, 21(25), 2245-2257. DOI: 10.2174/1568026621666211011101429
113. COUMARIN AND ITS DERIVATIVES – editorial (Matos MJ*) Molecules 2021
112. Study of a selected series of 3- and 4-arylcoumarins as antifungal agents against dermatophytic fungi: T. rubrum and T. mentagrophytes (Lucía Lopez Cisneros C, Cazar Ramírez ME, Bailon-Moscoso N, Guardado E, Borges F, Uriarte E, Matos MJ*) ChemistrySelect 2021, 6, 9981-9989. DOI: 10.1002/slct.202103099.
111. Multitarget therapeutic approaches for Alzheimer’s and Parkinson’s diseases: an opportunity or an illusion? (Matos MJ*) Fut Med Chem 2021, 13(15), 1301-1309. DOI: 10.4155/fmc-2021-0119.
110. Theobroma cacao L. compounds: Theoretical study and molecular modelling as inhibitors of main SARS-CoV-2 protease (Yañez O, Osorio MI, Areche C, Vasquez-Espinal A, Bravo J, Sandoval-Aldana A, Pérez-Donoso JM, González-Nilo F, Matos MJ, Osorio E, García-Beltrán O, Tiznado W) Biomed Pharmacother 2021, 140, 111764. DOI: 10.1016/j.biopha.2021.111764.
109. Medicinal Chemistry in Portugal and Spain: A Strong Iberian Alliance (Matos MJ*, Blanco M-J*) ACS Med Chem Lett 2021, 12(5), 667-668. DOI: 10.1021/acsmedchemlett.1c00143.
108. Combined 3D-QSAR and docking analysis for the design and synthesis of chalcones as potent and selective monoamine oxidase B inhibitors (Mellado M, González C, Mella J, Aguilar LF, Viña D, Uriarte E, Cuellar M, Matos MJ*) Bioorg Chem 2021, 108, 104689. DOI: 10.1016/j.bioorg.2021.104689.
107. Trending topics on coumarin and its derivatives in 2020 (Carneiro A, Matos MJ, Uriarte E, Santana L) Molecules 2021, 26, 501. https://doi.org/10.3390/molecules26020501.
106. 7‐Amidocoumarins as multitarget agents against neurodegenerative diseases: Substitution pattern modulation (Rodríguez-Enríquez F, Viña D, Uriarte E, Laguna R, Matos MJ*) ChemMedChem 2021, 16, 179-186. DOI: 10.1002/cmdc.202000454.
105. Chemical and biological analysis of 4-acyloxy-3-nitrocoumarins as trypanocidal agents (Salgado F, Moncada-Basualto M, Pozo-Martinez J, Liempi A, Kemmerling U, Maya JD, Jaque P, Borges F, Uriarte E, Matos MJ*, Olea-Azar C) Arab J Chem 2021, 14, 102975. DOI: 10.1016/j.arabjc.2020.102975.
2020
104. Sequential dual site-selective protein labelling enabled by lysine modification (Matos MJ, Brown L, Bernardim B, Guerreiro A, Jiménez-Osés G, Bernardes GJL) Bioorg Med Chem 2020, 28(22), 115783. 10.1016/j.bmc.2020.115783.
103. Adenosine receptor ligands: coumarin-chalcone hybrids as modulating agents on the activity of hARs (Vazquez-Rodriguez S, Vilar S, Kachler S, Klotz K-N, Uriarte E, Borges F, Matos MJ*) Molecules 2020, 25, 4306. DOI: 10.3390/molecules25184306.
102. Looking for new xanthine oxidase inhibitors: 3-Phenylcoumarins versus 2-phenylbenzofurans (Era B, Delogu GL, Pintus F, Fais A, Gatto G, Uriarte E, Borges F, Kumar A, Matos MJ*) Inter J Biolog Macromol 2020, 162, 774–780. DOI: 10.1016/j.ijbiomac.2020.06.152.
101. Discovery and Optimization of 3-Thiophenylcoumarins as Novel Agents Against Parkinson’s Disease: Synthesis, in vitro and in vivo Studies (Rodríguez-Enríquez F, Viña D, Uriarte E, Fontenla JA, Matos MJ*) Bioorg Chem 2020, 101, 103986. DOI: 10.1016/j.bioorg.2020.103986.
100. 3-Arylcoumarins as highly potent and selective monoamine oxidase B inhibitors: Which chemical features matter? (Mellado M, Mella J, González C, Viña D, Uriarte E, Matos MJ*) Bioorg Chem 2020, 101, 103964. DOI: 10.1016/j.bioorg.2020.103964.
99. Coumarin-rasagiline hybrids as potent and selective hMAO-B inhibitors, antioxidants and neuroprotective agents (Matos MJ*, Herrera Ibatá DM, Uriarte E, Viña D) ChemMedChem 2020, 15, 532-538. DOI: 10.1002/cmdc.202000018.
98. Structure-based optimization of coumarin hA3 adenosine receptor antagonists (Matos MJ*, Vilar S, Vazquez-Rodriguez S, Kachler S, Klotz K-N, Buccioni M, Delogu G, Santana L, Uriarte E, Borges F) J Med Chem 2020, 63(5), 2577-2587. DOI: 10.1021/acs.jmedchem.9b01572.
2019
97. Artificial intelligence applied to flavonoid data in food matrices (Guardado Yordi E, Koelig R, Matos MJ, Pérez Martínez A, Caballero Y, Santana L, Pérez Quintana M, Molina E, Uriarte E) Foods 2019, 8(11), 573-590. https://doi.org/10.3390/foods8110573.
96. Antibacterial activity and molecular docking studies of a selected series of hydroxy-3-arylcoumarins (Pisano MB, Kumar A, Medda R, Gatto G, Pal R, Fais A, Era B, Cosentino S, Uriarte E, Santana L, Pintus F, Matos MJ) Molecules 2019, 24, 2815-2829. https://doi.org/10.3390/molecules24152815.
95. Enhancement of the anti-aggregation activity of a molecular chaperone using a rationally designed post-translational modification (Lindstedt PR, Aprile FA, Matos MJ, Perni M, Bertoldo JB, Bernardim B, Peter Q, Corzana F, Jiménez-Osés G, Knowles TPJ, Dobson CM, Bernardes GJL, Vendruscolo M) ACS Central Sci 2019, 5(8), 1417-1424. https://doi.org/10.1021/acscentsci.9b00467
94. Design, synthesis and docking calculations of prenylated chalcones as selective monoamine oxidase B inhibitors with antioxidant activity (Mellado M, Salas CO, Uriarte E, Viña D, Jara-Gutiérrez C, Matos MJ*, Cuellar M) ChemistrySelect 2019, 4, 7698-7703. DOI: 10.1002/slct.201901282.
93. CCDC 1937910: Experimental Crystal Structure Determination (Matos MJ) CSD Communication 2019, DOI: 10.5517/ccdc.csd.cc231k7z.
92. Quaternization of vinyl/alkynyl pyridine enables ultrafast cysteine-selective protein modification and charge modulation (Matos MJ, Navo CD, Hakala T, Ferhati X, Guerreiro A, Hartmann D, Bernardim B, Saar KL, Compañón I, Corzana F, Knowles TPJ, Jiménez-Osés G, Bernardes GJL) Angew Chem Int Ed Engl 2019, 131, 6712-6716. DOI: 10.1002/ange.201901405.
91. Efficient and irreversible antibody-cysteine bioconjugation usingcarbonylacrylic reagents (Bernardim B, Matos MJ, Ferhati X, Compañón I, Guerreiro A, Akkapeddi P, Burtoloso ACB, Jiménez-Osés G, Corzana F, Bernardes GJL) Nat Protoc 2019, 4, 86-99. https://doi.org/10.1038/s41596-018-0083-9.
90. Novel coumarin-quinoline hybrids: design of multitarget compounds for Alzheimer's disease (Duarte Y, Fonseca A, Gutiérrez M, Adasme-Carreño F, Muñoz-Gutierrez C, Alzate-Morales J, Santana L, Uriarte E, Álvarez R, Matos MJ*) ChemistrySelect 2019, 4, 551-558. DOI: 10.1002/slct.201803222.
89. Synthesis, molecular docking and cholinesterase inhibitory activity of hydroxylated 2-phenylbenzofuran derivatives (Fais A, Kumar A, Medda R, Pintus F, Delogu F, Matos MJ, Era B, Delogu GL) Bioorg Chem 2019, 84, 302-308.
2018
88. Targeting α-(1,4)-glucosidase in Diabetes mellitus 1 type 2: the role of new synthetic coumarins as potent inhibitors (Figueroa-Benavides C, Matos MJ*, Veas R, Valenzuela-Barra G, Peñaloza-Amion M, Zapata G, Delogu G, Uriarte E, Santana L, Olea-Azar C, Delporte C*) Curr Top Med Chem 2018, 18(27), 2327-2337. doi: 10.2174/1568026619666181130113033.
87. PEGylated PLGA nanoparticles as a smart carrier to increase the cellular uptake of a coumarin-based monoamine oxidase B inhibitor (Fernandes C, Martins C, Fonseca A, Nunes R, Matos MJ, Silva R, Garrido J, Sarmento B, Remião F, Espinar-Otero F, Uriarte E, Borges F*) ACS Appl Mat Interf 2018, 10(46), 39557-39569. DOI: 10.1021/acsami.8b17224
86. Coumarin derivatives as promising xanthine oxidase inhibitors (Fais A, Era B, Asthana S, Sogos V, Medda R, Santana L, Uriarte E,Matos MJ, Delogu F, Kumar A*) Inter J Biolog Macromol 2018, 120, 1286-1293. https://doi.org/10.1016/j.ijbiomac.2018.09.001.
85. Synthesis and biological evaluation of homogenous thiol-linked NHC*-Au–albumin and –trastuzumab bioconjugates (Matos MJ, Labão-Almeida C, Sayers C,Dada O, Tacke M, Bernardes GJL*) Chem Eur J 2018, 24, 12250-12253. DOI: 10.1002/chem.201800872. Part of a Special Issue to commemorate young and emerging scientists.
84. A thioether-directed palladium-cleavable linker for targeted bioorthogonal drug decaging (Stenton BJ, Oliveira BL, Matos MJ, Sinatra L, Bernardes GJL) Chem Sci 2018, 9, 4185-4189.DOI: 10.1039/C8SC00256H.
83. Learning from nature: the role of albumin in drug delivery (Matos MJ*) Fut Med Chem 2018, 10(9), 983-985. DOI: 10.4155/fmc-2018-0053. Invited by the editor, Prof. Ben Walden.
82. Trends in patented chromones for skin diseases (Matos MJ*) Pharmac Pat Anal 2018,7(3), 107-109. DOI: 10.4155/ppa-2018-0004. Invited by the editor, Prof. Ben Walden.
81. A silicon-labelled amino acid suitable for late-stage fluorination and unexpected oxidative cleavage reactions in the preparation of a key intermediate in the Strecker synthesis (Scroggie KR, Alcock LJ, Matos MJ, Bernardes GJL, Perkins MV, Chalker JM*) Pept Sci 2018,110, e24069. DOI:10.1002/pep2.24069. Special Issue: Emerging Peptide Science in Australia.
80. Chemo and regioselective lysine modification on native proteins (Matos MJ, Oliveira B, Martínez-Sáez N, Guerreiro A, Cal PMSD, Bertoldo J, Maneiro M, Perkin E, Howard J, Deery MJ, Chalker JM, Corzana F, Jiménez-Osés G, Bernardes GJL*) JACS 2018, 140(11), 4004-4017. DOI: 10.1021/jacs.7b12874. [Highlighted in C&E news, 2018, Volume 96, Issue 11, p. 13, March 12, 2018 “Computer-designed reagent targets lysine for protein modification”; Phys.org “How to spark a chemical chain reaction”, March 9, 2018 (l)].
79. Evaluation of trypanocidal and antioxidant activities of a selected series of 3-amidocoumarins (Moncada-Basualto M, Lapier M, Maya JD, Matsuhiro B, Olea-Azar C, Delogu GL, Uriarte E, Santana L, Matos MJ*) Med Chem 2018, 14, 573-584. DOI: 10.2174/1573406414666180419113437.
78. Novel 2-pheynlbenzofurans derivatives as selective butyrylcholinesterase inhibitors for Alzheimer’s disease (Kumar A*, Pintus F, Di Petrillo A, Medda R, Caria P, Matos MJ, Viña D, Pieroni E, Delogu F, Era B, Delogu GL, Fais A) Sci Rep 2018, 8(1), 4424. DOI: 10.1038/s41598-018-22747-2.
77. Unexpected one step synthesis of 3-benzoyl-2-phenylbenzofurans under Wittig conditions (Begala M*, Caboni P, Matos MJ, Delogu GL) Tetrahedron Lett 2018, 59, 1711-1714. DOI: 10.1016/j.tetlet.2018.03.048.
76. Coumarins and adenosine receptors: new perceptions in structure-affinity relationships (Fonseca A, Matos MJ, Vilar S, Kachler S, Klotz K-N, Uriarte E, Borges F*) Chem Biol Drug Des 2018, 91, 245-256. doi: 10.1111/cbdd.13075.
2017
75. Coumarins as promising scaffold for the treatment of age-related diseases – an overview of the last five years (Delogu G, Matos MJ*) Curr Top Med Chem 2017, 17(29), 3173-3189 Doi: 10.2174/1568026618666171215094029.
74. Chemoselective Installation of Amine Bonds on Proteins Through Aza-Michael Ligation (Freedy AM, Matos MJ, Boutureira O, Corzana F, Guerreiro A, Akkapeddi P, Somovilla VJ, Rodrigues T, Nicholls K, Xie B, Jiménez-Osés G, Brindle KM, Neves AA, Bernardes GJL) JACS 2017, 139, 18365-18375. DOI: 10.1021/jacs.7b10702.
73. Coumarin versus chromone monoamine oxidase B inhibitors: Quo vadis? (Fonseca A, Reis J, Silva TB, Matos MJ, Bagetta D, Ortuso F, Alcaro S, Uriarte E, Borges F) J Med Chem 2017, 60(16), 7206-7212. DOI: 10.1021/acs.jmedchem.7b00918.
72. MAO inhibitory activity of bromo-2-phenylbenzofurans: synthesis, in vitro study and docking calculations (Delogu GL, Pintus F, May L, Matos MJ, Vilar S, Munín J, Fontenla JA, Hripcsak G, Borges F, Viña D) MedChemComm 2017, 8, 1788-1796. Doi: 10.1039/C7MD00311K.
71. In silico genotoxicity of coumarins: application of Phenol-Explorer food database to functional food science (Guardado Yordi E, Matos MJ, Pérez Martínez A, Tornes AC, Santana L, Molina E, Uriarte E) RSC Food & Function 2017, 8, 2958-2966. Doi: 10.1039/C7FO00402H.
70. New insights into highly potent tyrosinase inhibitors based on 3-heteroarylcoumarins: anti-melanogenesis and antioxidant activities, and computational molecular modeling studies (Pintus F, Matos MJ*, Vilar S, Hripcsak G, Varela C, Uriarte E, Santana L, Borges F, Medda R, Di Petrillo A, Era B, Fais A) Bioorg Med Chem 2017, 25, 1687-1695 DOI: 10.1016/j.bmc.2017.01.037.
69. Synthesis, antioxidant and antichagasic properties of a selected series of hydroxy-3-arylcoumarins (Robledo-O´Ryan N, Matos MJ*, Vazquez-Rodriguez S, Santana L, Uriarte E, Moncada-Basualto M, Mura F, Lapier M, Maya JD, Olea-Azar C) Bioorg Med Chem 2017, 25, 621-632 DOI: 10.1016/j.bmc.2016.11.033.
68. Trends in therapeutic drug conjugates for bacterial diseases: a patent review (Cal PMSD, Matos MJ*, Bernardes GJL) Exp Opin Therap Pat 2017, 27(2), 179-189. DOI: 10.1080/13543776.2017.1259411.
67. Heterocyclic antioxidants in nature: coumarins (Matos MJ*, Vazquez-Rodriguez S, Fonseca A, Uriarte E, Santana L, Borges F) Curr Org Chem 2017, 21(4), 311-324. DOI: 10.2174/1385272820666161017170652.
2016
66. Stoichiometric and irreversible cysteine-selective protein modification using carbonylacrylic reagents (Bernardim B, Cal PMSD, Matos MJ, Oliveira B, Martínez-Sáez N, Albuquerque I, Burtoloso A, Jiménez-Osés G, Bernardes GJL) Nat Commun 2016, 7, 13128. DOI: 10.1038/ncomms13128.
65. Structural elucidation of a series of 6-methyl-3-carboxamidocoumarins (Fonseca A, Gaspar A, Matos MJ, Gomes LR, Low JN, Uriarte E, Borges F) Magn Reson Chem 2016, 55(4), 373-378. DOI: 10.1002/mrc.4541.
64. 6-Methylcoumarin-N-(quinolin-6-yl)-3-carboxamide: crystal structure and Hirshfeld surface analysis (Gomes LR, Low JN, Fonseca A, Matos MJ, Borges F) Acta Cryst E 2016, E72, 1121-1125. doi: 10.1107/S2056989016011026.
63. Evaluation of antioxidant and antitrypanosomal properties of a selected series of synthetic 3-carboxamidocoumarins (Muñoz A, Fonseca A, Matos MJ*, Uriarte E, Santana L, Borges F, Figueroa R, Olea-Azar C) ChemistrySelect 2016, 1(15), 4957-4964. DOI: 10.1002/slct.201601336.
62. Crystal structures of three 6-substituted coumarin-3-carboxamide derivatives (Gomes LR, Low JN, Fonseca A, Matos MJ, Borges F) Acta Cryst E 2016, E72, 926-932. doi.org/10.1107/S2056989016008665.
61. Exploring coumarin potentialities: development of new MAO-B inhibitors based on the 6-methyl-3-carboxamidocoumarin scaffold (Fonseca A, Matos MJ, Reis J, Duarte Y, Gutiérrez M, Santana L, Uriarte E, Borges F) RSC Adv 2016, 6, 49764-49768. doi: 10.1039/c6ra05262b.
60. 2-Phenylbenzofuran derivatives as butyrylcholinesterase inhibitors: synthesis, biological activity and molecular modeling (Delogu G, Matos MJ, Fanti M, Era B, Medda R, Pieroni E, Fais A, Kumar A, Pintus F) Bioorg Med Chem Lett 2016, 26, 2308-2313. doi: 10.1016/j.bmcl.2016.03.039.
59. Progress in the development of small molecules as new human A3 adenosine receptor ligands based on the 3-thiophenylcoumarin core (Matos MJ*, Vilar S, Kachler S, Vazquez-Rodriguez S, Varela C, Delogu G, Hripcsak G, Santana L, Uriarte E, Klotz KN, Borges F) MedChemComm 2016, 7, 845-852. doi: 10.1039/C5MD00573F.
58. Facing Chagas’ disease: trypanocidal properties of new coumarin-chalcone scaffolds (Vazquez-Rodriguez S, Figueroa Guíñez R, Matos MJ, Olea-Azar C, Maya JD, Uriarte E, Santana L, Borges F) Med Chem 2016, 12(6), 537-543. doi: 10.2174/1573406412666160107111809.
2015
57. 3-Amidocoumarins as potential multifunctional agents against neurodegenerative diseases (Matos MJ*, Rodríguez-Enríquez F, Borges F, Santana L, Uriarte E, Estrada M, Rodríguez-Franco MI, Laguna R, Viña D*) ChemMedChem 2015, 10, 2071-2079. doi: 10.1002/cmdc.201500408.
56. Design and discovery of tyrosinase inhibitors based on the coumarin scaffold (Matos MJ*, Varela C, Vilar S, Hripcsak G, Borges F, Santana L, Uriarte E, Fais A, Di Petrillo A, Pintus F, Era B) RSC Adv 2015, 5, 94227-94233. doi: 10.1039/C5RA14465E.
55. Bioactive coumarins from marine sources: origin, structural features and pharmacological properties (Vazquez-Rodriguez S, Matos MJ, Borges F, Uriarte E, Santana L) Curr Top Med Chem 2015, 15(17), 1755-1766. doi: 10.2174/1568026615666150427125916.
54. Design, synthesis and antibacterial study of new potent and selective coumarin–chalcone derivatives for the treatment of tenacibaculosis (Vazquez-Rodriguez S, Lama López R, Matos MJ, Armesto-Quintas G, Serra S, Uriarte E, Santana L, Borges F, Muñoz Crego A, Santos Y) Bioorg Med Chem 2015, 23(21), 7045-7052. doi: 10.1016/j.bmc.2015.09.028.
53. Synthesis and pharmacological activities of non-flavonoid chromones: a patent review (from 2005-2015) (Matos MJ*, Vazquez-Rodriguez S, Uriarte E, Santana L, Borges F) Exp Opin Therap Pat 2015, 25(11), 1-20. doi: 10.1517/13543776.2015.1078790.
52. Development of novel adenosine receptor ligands based on the 3-amidocoumarin scaffold (Matos MJ*, Vilar S, Kachler S, Celeiro M, Vazquez-Rodriguez S, Santana L, Uriarte E, Hripcsak G, Borges F, Klotz KN) Bioorg Chem 2015, 61, 1-6. doi: 10.1016/j.bioorg.2015.05.008.
51. Study of coumarin-resveratrol hybrids as potent antioxidant compounds (Matos MJ*, Mura F, Vazquez-Rodriguez S, Borges F, Santana L, Uriarte E, Olea-Azar C) Molecules 2015, 20, 3290-3308. doi: 10.3390/molecules20023290.
50. Potent and selective MAO-B inhibitory activity: amino- versus nitro-3-arylcoumarin derivatives (Matos MJ*, Rodríguez-Enríquez F, Vilar S, Santana L, Uriarte E, Hripcsak G, Estrada M, Rodríguez-Franco MI, Viña D) Bioorg Med Chem Lett 2015, 25, 642-648. doi: 10.1016/j.bmcl.2014.12.001.
49. Oxidative stress and neurodegenerative diseases: looking for a therapeutic solution inspired on benzopyran chemistry (Gaspar A, Milhazes N, Santana L, Uriarte E, Borges F, Matos MJ*) Curr Top Med Chem 2015, 15(5), 432-445. doi: 10.2174/1568026614666141229124141.
48. The interest of antioxidants agents in parasitic diseases. The case study of coumarins (Figueroa-Guinez R, Matos MJ, Vazquez-Rodriguez S, Santana L, Uriarte E, Olea-Azar C, Borges F, Diego Maya J) Curr Top Med Chem 2015, 15(9), 850-856. doi: 10.2174/1568026615666150220113155.
47. In silico clastogenic activity of dietary phenolic acids (Guardado Yordi E, Matos MJ, Castro Pupo R, Santana L, Uriarte E, Molina Pérez E) LWT Food Sci Tech 2015, 61, 216-223. doi: 10.1016/j.lwt.2014.11.012.
46. Potential pharmacological uses of chalcones: a patent review (from June 2011-2014) (Matos MJ*, Vazquez-Rodriguez S, Uriarte E, Santana L) Exp Opin Therap Pat 2015, 25(3), 351-366. doi: 10.1517/13543776.2014.995627.
2014
4. Insights into the interaction of novel coumarin derivatives with human A3 adenosine receptors (Matos MJ*, Vilar S, Kachler S, Fonseca A, Santana L, Uriarte E, Borges F, Tatonetti NP, Klotz KN) ChemMedChem 2014, 9, 2245-2253 (paper selected as back cover of the issue). doi: 10.1002/cmdc.201402205.
44. Insights into functional and structural properties of 3-arylcoumarins as an interesting scaffold in MAO-B inhibition (Matos MJ*, Vilar S, García-Morales V, Tatonetti NP, Uriarte E, Santana L, Viña D) ChemMedChem 2014, 9, 1488-1500. doi: 10.1002/cmdc.201300533.
43. Synthesis and electrochemical study of new 3-(hydroxyphenyl)benzo[f]coumarins (Matos MJ, Janeiro P, Santana L, Uriarte E, Oliveira-Brett AM) J Electroanal Chem 2014, 726, 62-70. doi: 10.1016/j.jelechem.2014.05.003.
42. Synthesis, pharmacological study and docking calculations of new benzo[f]coumarin derivatives as dual inhibitors of enzymatic systems involved in neurodegenerative diseases (Matos MJ*, Janeiro P, González Franco RM, Vilar S, Tatonetti NP, Santana L, Uriarte E, Borges F, Fontanela JA, Viña D) Fut Med Chem 2014, 6(4), 371-383. doi: 10.4155/fmc.14.9.
41. Chromone: a valid scaffold in medicinal chemistry (Gaspar A, Matos MJ, Garrido J, Uriarte E, Borges F) Chem Rev 2014, 114 (9), 4960-4992. doi: 10.1021/cr400265z.
2013
40. Synthesis and evaluation of antioxidant and trypanocidal properties of a selected series of coumarin derivatives (Figueroa Guíñez R, Matos MJ*, Vazquez-Rodriguez S, Santana L, Uriarte E, Olea-Azar C, Maya JD) Fut Med Chem 2013, 5(16), 1911-1922. DOI: 10.4155/fmc.13.147.
39. Comparative study of the 3-phenylcoumarin scaffold: synthesis, X-ray structural analysis and semiempirical calculations of a selected series of compounds (Matos MJ*, Vilar S, Tatonetti NP, Santana L, Uriarte E) J Mol Struct 2013, 1050, 185-191. DOI: 10.1016/j.molstruc.2013.07.037.
38. Synthesis, electrochemical and biological studies on novel coumarin-chalcone hybrid compounds (Pérez-Cruz F, Vazquez-Rodriguez S, Matos MJ, Herrera-Morales A, Villamena F, Das A, Gopalakrishnan B, Olea-Azar C, Santana L, Uriarte E) J Med Chem 2013, 56, 6136-6145. DOI: 10.1021/jm400546y.
37. QSAR and complex network recognition of miRNAs in stem cells (Molina E, Uriarte E, Santana L, Matos MJ, Borges F) Curr Bioinf 2013, 8, 438-451. DOI: 2212-392X/13.
36. Synthesis and adenosine receptors binding affinities of a series of 3-arylcoumarins (Matos MJ*, Hogger V, Gaspar A, Kachler S, Borges F, Uriarte E, Santana L, Klotz KN) J Pharm Pharmacol 2013, 65, 1590-1597. doi: 10.1111/jphp.12135.
35. (1S,2S,5S)-2-Methyl-3-oxo-5-(prop-1-en-2-yl)cyclohexane-1-carbonitrile (Rivadulla ML, Fall A, González M, Matos MJ*) Acta Crys 2013, E69, o799. doi: 10.1107/S1600536813011197.
34. [(2S,3aR,6aR)-5-Oxohexahydrofuro[3,2-b]furan-2-yl]methyl acetate (González M, Martínez A, Rivadulla ML, Matos MJ*) Acta Cryst 2013, E69, o772. doi: 10.1107/S1600536813010313.
33. Synthesis of coumarin-chalcone hybrids and evaluation of their antioxidant and trypanocidal properties (Vazquez-Rodriguez S, Figueroa-Guíñez R, Matos MJ, Santana L, Uriarte E, Lapier M, Maya JD, Olea-Azar C) MedChemComm 2013, 4, 993-1000. doi: 10.1039/c3md00025g.
32. MAO inhibitory activity of 2-arylbenzofurans versus 3-arylcoumarins: synthesis, in vitro study and docking calculations (Ferino G, Cadoni E, Matos MJ*, Quezada E, Uriarte E, Santana L, Vilar S, Tatonetti NP, Yáñez M, Viña D, Picciau C, Serra S, Delogu G) ChemMedChem 2013, 8, 956-966. doi: 10.1002/cmdc.201300048.
31. Remarkable antioxidant properties of a series of hydroxy-3-arylcoumarins (Matos MJ*, Pérez-Cruz F, Vazquez-Rodriguez S, Uriarte E, Santana L, Borges F, Olea-Azar C) Bioorg Med Chem 2013, 21, 3900-3906. doi: 10.1016/j.bmc.2013.04.015.
30. Synthesis, NMR characterization, X-ray structural analysis and theoretical calculations of amide and ester derivatives of the coumarin scaffold (Matos MJ*, Uriarte E, Santana L, Vilar S) J Mol Struct 2013, 1041, 144-150. doi: 10.1016/j.molstruc.2013.03.014.
29. Chalcone-based derivatives as new scaffolds for hA3 adenosine receptor antagonists (Vazquez-Rodriguez S, Matos MJ, Santana L, Uriarte E, Borges F, Kachler S, Klotz KN) J Pharm Pharmacol 2013, 65, 697-703. doi: 10.1111/jphp.12028.
28. Novel (coumarin-3-yl)carbamates as selective MAO-B inhibitors: synthesis, in vitro and in vivo assays, theoretical evaluation of ADME properties and docking study (Matos MJ*, Vilar S, Gonzalez-Franco RM, Uriarte E, Santana L, Friedman C, Tatonetti NP, Viña D, Fontenla JA) Eur J Med Chem 2013, 63, 151-161. doi: 10.1016/j.ejmech.2013.02.009.
27. Synthesis and structure-activity relationships of novel amino/nitro substituted 3-arylcoumarins as antibacterial agents (Matos MJ*, Vazquez-Rodriguez S, Santana L, Uriarte E, Fuentes-Edfuf C, Santos Y, Muñoz-Crego A) Molecules 2013, 18, 1394-1404. doi: 10.3390/molecules18021394.
26. New hydroxylated 3-arylcoumarins, synthesis and electrochemical study (Janeiro P, Matos MJ, Santana L, Uriarte E, Oliveira-Brett AM) J Electroanal Chem 2013, 689, 243-251. doi: 10.1016/j.jelechem.2012.10.020.
25. Targeting adenosine receptors with coumarins: synthesis and binding activities of amide and carbamate derivatives (Matos MJ*, Gaspar A, Kachler S, Klotz KN, Borges F, Santana L, Uriarte E) J Pharm Pharmacol 2013, 65, 30-34. doi: 10.1111/j.2042-7158.2012.01571.x.
2012
24. Monoamine Oxidase as a Target in Medicinal Chemistry and Drug Discovery (Matos MJ*, Viña D*) Curr Top Med Chem 2012, 12, 2115. DOI: 10.2174/156802612805220039.
23. Focusing on new monoamine oxidase inhibitors: differently substituted coumarins as an interesting scaffold (Matos MJ, Viña D, Vazquez-Rodriguez S, Uriarte E, Santana L) Curr Top Med Chem 2012, 12, 2210-2239. doi: 10.2174/156802612805220002.
22. Monoamine oxidase inhibitors: ten years of docking studies (Ferino G, Vilar S, Matos MJ, Uriarte E, Cadoni E) Curr Top Med Chem2012, 12, 2145-2162. doi: 10.2174/156802612805220048.
21. N-(2-Oxo-2H-chromen-3-yl)cyclohexanecarboxamide (Matos MJ*, Santana L, Uriarte E) Acta Cryst 2012, E68, o3447-o3448. doi: 10.1107/S1600536812047903.
20. Improved synthesis of 3-(aminoaryl)coumarins (Matos MJ*, Gaspar A, Borges F, Uriarte E, Santana L) Org Prep Proc Int 2012, 44, 522-526. doi: 10.1080/00304948.2012.730937.
19. 3-Phenylcoumarin (Matos MJ*, Santana L, Uriarte E) Acta Cryst 2012, E68, o2645. doi: 10.1107/S1600536812034277.
18. Looking for new targets: simple coumarins as antibacterial agents (Matos MJ*, Vazquez-Rodriguez S, Santana L, Uriarte E, Fuentes-Edfuf C, Santos Y, Muñoz-Crego A) Med Chem 2012, 8, 1140-1145. doi: 10.2174/157340612804075205.
17. In search for new chemical entities as adenosine receptor ligands: development of agents based on benzo-γ-pyrone skeleton (Gaspar A, Reis J, Matos MJ, Uriarte E, Borges F) Eur J Med Chem 2012, 54, 914-918. doi: 10.1016/j.ejmech.2012.05.033.
16. Monoamino oxidase A: an interesting pharmacological target for the development of multi-target QSAR models (Molina E, Sobarzo-Sánchez E, Speck-Planche A, Matos MJ*, Uriarte E, Santana L, Yáñez M, Orallo F) Mini Rev Med Chem 2012, 12, 947-958. doi: 10.2174/138955712802762383.
15. 8-Substituted-3-arylcoumarins as potent and selective MAO-B inhibitors: synthesis, pharmacological evaluation and docking studies (Viña D, Matos MJ*, Ferino G, Cadoni E, Laguna R, Borges F, Uriarte E, Santana L) ChemMedChem 2012, 7, 464-470 (According to the Thomson Reuters Web of Science, this Full Paper was among the top 10 most cited articles published by ChemMedChem in 2012). doi: 10.1002/cmdc.201100538.
14. Tyrosine-like condensed derivatives as tyrosinase inhibitors (Matos MJ*, Santana L, Uriarte E, Serra S, Corda M, Fadda MB, Era B, Fais A) J Pharm Pharmacol 2012, 64, 742-746. doi: 10.1111/j.2042-7158.2012.01467.x.
13. Structural alerts for predicting clastogenic activity of pro-oxidant flavonoid compounds: quantitative structure–activity relationship study (Guardado E, Molina E, Matos MJ, Uriarte E) J Biomol Screen 2012, 17(2), 216-224. doi: 10.1177/1087057111421623.
12. Hydroxycoumarins as selective MAO-B inhibitors (Serra S, Ferino G, Matos MJ, Vázquez-Rodríguez S, Delogu G, Viña D, Cadoni E, Santana L, Uriarte E) Bioorg Med Chem Lett 2012, 22, 258-261. doi: 10.1016/j.bmcl.2011.11.020.
11. 3-Substituted coumarins as dual inhibitors of AChE and MAO for the treatment of Alzheimer´s disease (Viña D, Matos MJ*, Yáñez M, Santana L, Uriarte E) MedChemComm 2012, 3, 213-218 (Featured in the top 10% of the most highly cited articles published in the latest Impact Factor window 2011-2012). doi: 10.1039/c1md00221j.
2008-2011
10. Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors (Matos MJ*, Terán C, Pérez-Castillo Y, Uriarte E, Santana L, Viña D) J Med Chem 2011, 54, 7127-7137. doi: dx.doi.org/10.1021/jm200716y.
9. MAO inhibitory activity modulation: 3-phenylcoumarins versus 3-benzoylcoumarins (Matos MJ, Vázquez-Rodriguez S, Uriarte E, Santana L, Viña D) Bioorg Med Chem Lett 2011, 21, 4224-4227. doi: 10.1016/j.bmcl.2011.05.074.
8. New halogenated phenylcoumarins as tyrosinase inhibitors (Matos MJ*, Santana L, Uriarte E, Delogu G, Corda M, Fadda MB, Era B, Fais A) Bioorg Med Chem Lett 2011, 21, 3342-3345. doi: 10.1016/j.bmcl.2011.04.012.
7. Synthesis of 3-arylcoumarins via Suzuki-cross-coupling reactions of 3-chlorocoumarin (Matos MJ*, Vazquez-Rodriguez S, Borges F, Santana L, Uriarte E) Tetrahedron Lett 2011, 52, 1225-1227. doi: 10.1016/j.tetlet.2011.01.048.
6. Regioselective synthesis of different bromo substituted 3-arylcoumarins (Matos MJ*, Delogu G, Podda G, Santana L, Uriarte E) Synthesis 2010, 16, 2763-2766. doi: 10.1055/s-0029-1218835.
5. New halogenated 3-phenylcoumarins as potent and selective MAO-B inhibitors (Matos MJ*, Viña D, Janeiro P, Borges F, Santana L, Uriarte E) Bioorg Med Chem Lett 2010, 20, 5157-5160. doi: 10.1016/j.bmcl.2010.07.013.
4. Synthesis and evaluation of 6-methyl-3-phenylcoumarins as potent and selective MAO-B inhibitors (Matos MJ*, Viña D, Picciau C, Orallo F, Santana L, Uriarte E) Bioorg Med Chem Lett 2009, 19, 5053-5055. doi: 10.1016/j.bmcl.2009.07.039.
3. A new series of 3-phenylcoumarins as potent and selective MAO-B inhibitors (Matos MJ*, Viña D, Quezada E, Picciau C, Delogu G, Orallo F, Santana L, Uriarte E) Bioorg Med Chem Lett 2009, 19, 3268-3270. doi: 10.1016/j.bmcl.2009.04.085.
2. Tyrosinase inhibitor activity of the coumarin-resveratrol hybrids (Fais A, Corda M, Era B, Fadda MB, Matos MJ, Quezada E, Santana L, Picciau C, Podda G, Delogu G) Molecules 2009, 14, 2514-2520. doi: 10.3390/molecules14072514.
1. Synthesis of regio-isomeric functionalized benzodifurans and angelicins (Quezada E, Delogu G, Viña D, Podda G, Matos MJ, Picciau C) Helv Chim Acta 2009, 92, 1309-1314. doi: 10.1002/hlca.200800421.
Book Chapters
5. Lysine bioconjugation on native albumin with a sulfonyl acrylate reagent (Matos MJ, Jiménez-Osés G, Bernardes GJL*) 2019 – Chapter 3. Sam Massa and Nick Devoogdt (eds.), Bioconjugation: Methods and Protocols, Methods in Molecular Biology, vol. 2033, https://doi.org/10.1007/978-1-4939-9654-4_3, Springer Science+Business Media, LLC, part of Springer Nature.
4. Antioxidant and Pro-Oxidant Effects of Polyphenolic Compounds and Structure-Activity Relationship Evidence (Guardado Yordi EG, Molina E, Matos MJ, Uriarte E) 2012 - Nutrition, Well-Being and Health, Jaouad Bouayed and Torsten Bohn (Ed.), ISBN: 978-953-51-0125-3, InTech.
3. Umbelliferone: a natural scaffold suitable for the synthesis of ortho-acetylhydroxycoumarins via Fries rearrangement reaction (Vazquez-Rodriguez S, Matos MJ, Uriarte E, Borges F) 2016 - Comprehensive Organic Chemistry Experiments for the Laboratory Classroom, C.A. Afonso, D.P. Simão (Eds.), 2016, Royal Society of Chemistry, ISBN 9781849739634.
2. Coumarins: an important class of phytochemicals (Matos MJ, Santana L, Uriarte E, Abreu O, Molina E, Yordi EG) 2015 – Phytochemicals, Jaouad Bouayed and Torsten Bohn (Ed.), ISBN 978-953-51-4156-3, InTech, http://dx.doi.org/10.5772/59982.
1. Ellagic acid: its importance in diet (Yordi E, Martínez AP, Pérez RDA, Molina E, Santana L, Uriarte E, Abreu OA, Matos MJ) 2016 – Chapter 3 pp. 73-110. Ellagic Acid: Food Sources, Potential Role in Human Health and Antioxidant Effects, Edmund Brewer (Ed.), ISBN 978-1-63485-658-4, Nova Science Publishers.
Book
Patent
Use of 6-substituted 3-phenylcoumarines as selective monoamine oxidase B inhibitors for treating neurodegenerative diseases and obesity and preparation of new derivatives, Number: WO2010086484 A1. Priority country: Spain. Date: 05/08/2010. Titular entity: USC. Authors: Santana L, Orallo F, Viña D, Matos MJ, Quezada E, Yañez M, Vilar S, Uriarte E.
Cover illustrations
Design of 3-Phenylcoumarins and 3-Thienylcoumarins as Potent Xanthine Oxidase Inhibitors: Synthesis, Biological Evaluation, and Docking Studies
2023
Cover of the ChemMedChem. The front cover picture shows the best docking pose of the most active inhibitor of a series of 5,7-dihydroxy-3-arylcoumarins in the binding pocket of xanthine oxidase. The ligand-target interaction is highlighted by expanding the pocket. The primary function of xanthine oxidase inhibitors is to reduce serum urate levels in patients with gout. These molecules may present antioxidant properties by reducing the production of reactive oxygen species derived from purine metabolism. Gout is caused by an excess of uric acid in the blood. This disease is represented by a hand with small sharp crystals around the joints. These crystals can cause the joint to become red, swollen, and painful.
Cover design by Maria João Matos. Most of the components have been generated by the authors. Graphical components reused with permission from creator: Servier Medical Art (all our resources are freely available for your use, under the Creative Commons Attribution 3.0 Unported license) or ChemDraw (PerkinElmer 22.2).
Synthesis and Vasorelaxant Activity
of Nitrate-Coumarin Derivatives
2022
Cover of the ChemMedChem. The Front Cover shows the most active molecule of a series of nitrate coumarins, coumarin-7-yl-methyl nitrate, that “magically” releases nitric oxide into the bloodstream, leading to a vasodilatory effect. Synthesized nitrate-coumarins show potent vasodilator activity on isolated rat aortic rings deprived of endothelium, with a higher effect on those rings pre-contracted with phenylephrine than potassium chloride. This suggests that the opening of potassium channels may be involved in their vasorelaxant mechanism of action. Cover design by Maria João Matos with graphic components reused with permission: Red blood cells flowing background by ‘Macrovector—Freepik.com’ available at Freepik; Tale composition with magic wand and magician hat by ’Starline—Freepik.com’ available at Freepik. More information can be found in the Research Article by Maria João Matos et al..
Artificial intelligence applied to flavonoid data in food matrices
2019
Cover of the Foods issue related to the manuscript "Artificial intelligence applied to flavonoid data in food matrices. Foods 2019, 8(11), 573-590."
Insights into the interaction of novel coumarin derivatives with human A3 adenosine receptors
2014
Cover of the Foods issue related to the manuscript: "Insights into the interaction of novel coumarin derivatives with human A3 adenosine receptors. ChemMedChem 2014, 9, 2245-2253."